Role of voltage-gated calcium channels in ascending pain pathways - Wikidata - wikimedia - TriplyDB

Role of voltage-gated calcium channels in ascending pain pathways

Role of voltage-gated calcium channels in ascending pain pathways

http://www.wikidata.org/entity/Q30436560

about

The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome Fragile X mental retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium channel density Cellular and Molecular Mechanisms of Pain The Concise Guide to PHARMACOLOGY 2013/14: ion channels Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist.Characterization of novel cannabinoid based T-type calcium channel blockers with analgesic effects.1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain.Role of antispasmodics in the treatment of irritable bowel syndrome.Identification of CaV channel types expressed in muscle afferent neurons.[EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands.A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY.Persistent inflammation alters the density and distribution of voltage-activated calcium channels in subpopulations of rat cutaneous DRG neurons TRPA1 has a key role in the somatic pro-nociceptive actions of hydrogen sulfide Role of opioid system in verapamil-induced antinociception in a rat model of orofacial pain.Pharmacogenetics of new analgesics.Z944: a first in class T-type calcium channel modulator for the treatment of pain.Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca²⁺ channels in humanized mouse sensory neurons.Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels.Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides.The complex actions of sumatriptan on rat dural afferents Venom peptides as a rich source of cav2.2 channel blockers.SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.Development of a spontaneously active dorsal root ganglia assay using multiwell multielectrode arrays Phorbol ester modulation of Ca2+ channels mediates nociceptive transmission in dorsal horn neurones.N-type voltage gated calcium channels mediate excitatory synaptic transmission in the anterior cingulate cortex of adult mice.Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.Heantos-4, a natural plant extract used in the treatment of drug addiction, modulates T-type calcium channels and thalamocortical burst-firing.Targeting voltage-gated calcium channels for neuropathic pain management.Combination drug therapy for chronic pain: a call for more clinical studies.T-type calcium channels inhibitors: a patent review.Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse.Signaling complexes of voltage-gated calcium channels Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.Omega-conotoxins as experimental tools and therapeutics in pain management.Understanding and treating painful diabetic neuropathy: time for a paradigm shift.

P2860

Q28085351-6661F838-5386-42B7-9CAF-57227669CC07 Q28241278-E0BB2C6C-2938-4F6B-A663-61965FE9A27F Q28513294-FCCF848E-33AC-43DF-9D33-0BEEB8BD2A7D Q29011961-A3C07A8E-325F-4F0A-8931-C64CE8AD9348 Q30486735-C3320A2D-A938-4E3D-89BA-66500C890990 Q30541205-EE0FA0F8-093D-4B0D-8CC5-F8DB8E620EBC Q30631622-074F68ED-92F4-4870-9FB0-A8A624D8E0F5 Q31170459-168E6E4D-C0B8-463C-BD73-75C6C60D3BCF Q33661077-DE0ECD94-9D9D-4A22-9A1C-859A4A5E1953 Q33702443-4A6A39DB-6FDB-4C40-848F-97A030692F86 Q33824948-1AEDE816-E587-42B2-9F6F-517A6558AF17 Q33842774-7EB38B6D-4779-4F9C-90BB-D1DDCA3E63DB Q34233536-1F63550C-7059-4DD9-9719-56554D4E4154 Q34291550-AD8B4C56-438E-4435-9073-82264F5761B1 Q34299558-0AE057D6-8FE9-4EC8-9115-3BCFE4D3A932 Q34447592-32AFB3D2-CC8C-4534-AC41-A9410D2AE446 Q34787382-D96DD24A-B060-4A24-9441-8BF0C7214311 Q35005640-B992A0EA-09FE-476A-8715-91586039BEF8 Q35289649-280FF3E8-9214-4C0B-94FA-3EDA2EDB9951 Q35464108-3E2A562D-EB7C-49C5-806D-E213C3652A8A Q35561043-8E34C130-F4BC-4011-8FEA-F4CA4CD1D1A5 Q36159142-15979B75-F83B-4839-898D-5D4EA46E1F57 Q36318896-32721FD0-1184-4D8A-A323-573B0A8D98A6 Q36641373-0A75759E-F68A-4C17-A516-793DF76CC0DE Q36807192-709BB0EF-4FDD-478E-A2FB-55C88E37A119 Q37009051-EB107607-070D-4EE8-B2AA-85F9DB60B237 Q37074848-AEA8BD0B-9934-466A-9B74-6A1DCF5CDB3A Q37098011-E5B5E167-AE59-4DED-8C27-6C02B7EBD526 Q37277479-BC8AF1A0-931A-4868-985B-C63011404DA9 Q37348436-CAB9E9AE-0005-4D94-8FA8-C439D8023071 Q37360619-B6FE2042-56A8-40C4-A080-555008EB1973 Q37476509-5B4D0CD1-0A8B-4E6C-9924-35C40555BDF1 Q37605352-EB8E4AAC-89AD-41FD-B383-2BFF2968B92B Q37790054-E85D6EB0-5E20-44BD-8A7A-D3E18048BFAB Q37810605-FF0E668D-AB49-48D4-B924-E71183D7521B Q37855928-0A3AEFA2-D4F4-4B60-BC99-92C0AF5B3435 Q37915192-1DB4ABA0-8675-4E9D-A4B5-AFD7BCC88B10 Q38020929-F22E6F05-8E29-408C-9987-59E75DA9A9E4 Q38087443-1867ACD2-278E-4370-A7A0-428C3161ABAE Q38394422-85486F67-4253-420F-9B6B-7EC572BF4250

P2860

Role of voltage-gated calcium channels in ascending pain pathways

http://www.wikidata.org/entity/Q30436560

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Role of voltage-gated calcium channels in ascending pain pathways

@ast

Role of voltage-gated calcium channels in ascending pain pathways

@en

type

label

Role of voltage-gated calcium channels in ascending pain pathways

@ast

Role of voltage-gated calcium channels in ascending pain pathways

@en

prefLabel

Role of voltage-gated calcium channels in ascending pain pathways

@ast

Role of voltage-gated calcium channels in ascending pain pathways

@en

P1433

Q30436560-12148DC1-21D0-4D14-A597-3F91DB779200

P1476

Q30436560-ECF33D6B-5BD0-4693-9D00-A75960424949

P2093

Q30436560-311DB1C5-573E-4EFE-A349-36C1F3201B55

Q30436560-6D781AAA-F333-47B3-AB09-7B20F92170CF

Q30436560-EB7E6CD7-CB8A-40F8-A614-111666B1DF63

P2860

Q30436560-0474BA65-7843-462D-8B83-90115F03CDD3

Q30436560-0546C4F1-979C-483A-ADBB-167D58BC6453

Q30436560-07352019-4CD8-43DA-9038-28DD22C3013C

Q30436560-0E403953-F553-4848-84BF-1A37B2B6CAE4

Q30436560-0F413ED2-D665-45C3-A5C0-0BD76AA115B8

Q30436560-1E00AD9A-678C-410F-A16D-797337C4E232

Q30436560-1F8277F2-20A1-42D1-9333-6012DB49B261

Q30436560-23A53236-0A71-4FD7-8CAA-B40D31FD80D6

Q30436560-23FFAFAE-EB1F-4E39-A201-9CCECEE692B4

Q30436560-2440C8DD-EBF9-4104-9917-BA21DAAD8D54

P304

Q30436560-A2C42261-07E2-42CD-8FCE-941BFC873D84

P31

Q30436560-6CBF2513-BA38-4BFE-AEB4-5FBD00023767

P356

Q30436560-76066AA8-D2A6-4727-926F-0D9D36F18982

P433

Q30436560-AC414D4A-5E86-4E35-8147-CACC8BB599EE

P478

Q30436560-C17FDA77-4A14-42D7-BAED-F5F0F9740F2B

P50

Q30436560-005F288A-1117-4F65-B5CC-60723344A969

Q30436560-428941E5-84A9-4E3C-A6E8-59BF1249DF3D

P577

Q30436560-39EF5766-12BE-4AA3-8A9F-5B8581050303

P5875

Q30436560-C37D99D2-1A2D-43D8-B4C4-5F4EBEB40957

P698

Q30436560-48FDFF8D-873C-41A1-8FB1-3192A1563130

P932

Q30436560-D40C43E2-E108-4BB7-9461-1AEEB929B37F

P356

J.BRAINRESREV.2008.12.021

P1433

Brain Research Reviews

P1476

Role of voltage-gated calcium channels in ascending pain pathways

@en

P2093

Slobodan M Todorovic

http://www.w3.org/2001/XMLSchema#string

Stephen P Arneric

http://www.w3.org/2001/XMLSchema#string

Terrance P Snutch

http://www.w3.org/2001/XMLSchema#string

P2860

A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatement

Alternative splicing in the C-terminus of CaV2.2 controls expression and gating of N-type calcium channels

Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter

Molecular mechanisms of nociception

Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels

Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel.

Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes

Altered pain responses in mice lacking alpha 1E subunit of the voltage-dependent Ca2+ channel.

Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker.

The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors.

P304

84-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BRAINRESREV.2008.12.021

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Richard J. Lewis

Gerald W. Zamponi

P577

2008-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23931237

http://www.w3.org/2001/XMLSchema#string

P698

19162069

http://www.w3.org/2001/XMLSchema#string

P932

2692704

http://www.w3.org/2001/XMLSchema#string